Analysis of Pyrroloquinoline Quinone (PQQ)

1. Studied Conditions

• PQQ has been studied for its potential effects on cognitive health, such as memory and attention improvement.
• It has been researched for its impact on mitochondrial function and energy metabolism, possibly aiding in conditions such as chronic fatigue.
• Researchers have also looked into its potential in reducing oxidative stress and promoting heart health.
• Some studies have investigated PQQ for its potential neuroprotective effects and implications in neurodegenerative diseases.

2. Efficacy in Treating Studied Conditions

• The evidence for PQQ's effectiveness in treating specific conditions is still emerging, with some studies showing promise, particularly in improving cognitive function and reducing oxidative damage.
• Clinical trials are limited, and more research is needed to confirm the efficacy of PQQ in treating the studied conditions.

3. Health Benefits

• PQQ may support cognitive health by enhancing nerve growth factor production and protecting neurons from oxidative damage.
• It could potentially improve energy metabolism through the stimulation of mitochondrial biogenesis.
• Antioxidant properties of PQQ may contribute to overall reduction in oxidative stress, potentially benefiting heart health and slowing aging processes.
• Some evidence suggests that PQQ may have an anti-inflammatory effect, which could be beneficial for chronic inflammatory conditions.

4. Downsides

• While generally considered safe, there is a lack of long-term safety data for the use of PQQ supplements.
• Some individuals may experience mild side effects, such as headaches or fatigue when taking PQQ supplements.
• Due to limited research, potential interactions with medications or other supplements are not fully understood.

5. Genetic Variations and PQQ

• Current research has not definitively linked PQQ efficacy or safety to specific genetic variations.
• Genetic differences in mitochondrial function or antioxidant enzyme production could theoretically influence how an individual responds to PQQ, but this area requires further investigation.
• As personalized medicine evolves, genetic testing may provide more insights into who might benefit most from PQQ supplementation.

Pyrroloquinoline quinone (PQQ) Research Summary

PQQ is a bacterial redox cofactor and potential antioxidant that may be considered an essential nutrient. It has shown neuroprotective effects against various neurotoxins and oxidative stress, potentially aiding in the prevention of neurodegenerative diseases like Parkinson's disease and Alzheimer's disease. PQQ inhibits the formation of amyloid fibrils associated with Parkinson's disease and protects against beta-amyloid-induced neurotoxicity relevant to Alzheimer's disease pathology.

Neuroprotection and Parkinson's Disease

• PQQ prevents cell death and DNA fragmentation caused by oxidative stress-inducing neurotoxins such as 6-hydroxydopamine (6-OHDA) and hydrogen peroxide (H2O2).
• PQQ's antioxidant action is linked to scavenging superoxide reactive oxygen species.
• PQQ inhibits the aggregation of truncated alpha-synuclein, which is implicated in Parkinson's disease, and reduces its cytotoxicity.
• PQQ's interaction with the protein DJ-1, which is associated with familial early-onset Parkinson's disease, suggests a role in maintaining the active form of DJ-1 and protecting against oxidative stress.

Cardioprotection

• PQQ reduces the size of heart tissue damage (infarct size) and improves cardiac function after ischemic events.
• PQQ acts as a free radical scavenger, enhancing survival at high doses of lethal radiation and promoting hematopoietic recovery following sublethal radiation exposure.

Bone Health

• PQQ inhibits the formation of osteoclasts, cells that break down bone tissue, by interfering with the activation of NFATc1, a transcription factor essential for osteoclast differentiation.
• PQQ's inhibition of osteoclast formation may involve downregulation of c-Fos and NFATc1 activation, offering potential therapeutic applications for preventing excessive bone resorption in diseases like osteoporosis.

Antioxidant Properties

• PQQ has been shown to protect neurons from oxidative stress and cell death in various cell culture and animal models.
• It exerts anti-melanogenic effects, potentially useful for treating hyperpigmentation disorders.
• PQQ's redox state plays a crucial role in its biological activity, acting as an antioxidant in certain contexts while potentially behaving as a pro-oxidant in others.

Challenges and Considerations

• Initial in vitro tests showed weak positive results for chromosomal abnormalities, but further testing in human lymphocytes and in vivo in mice did not indicate genotoxic activity, suggesting that PQQ disodium salt does not exhibit genotoxic activity in vivo.
• High doses of PQQ have been linked to kidney damage in rats, indicating a need for careful consideration of dosage in potential therapeutic applications.

References:

1. GLUCOSE DEHYDROGENASE OF BACTERIUM ANITRATUM: AN ENZYME WITH A NOVEL PROSTHETIC GROUP
2. Pyrroloquinoline quinone (PQQ) and quinoprotein enzymes
3. Levels of pyrroloquinoline quinone in various foods
4. Simple and sensitive method for pyrroloquinoline quinone (PQQ) analysis in various foods using liquid chromatography/electrospray-ionization tandem mass spectrometry
5. Characterization of pyrroloquinoline quinone amino acid derivatives by electrospray ionization mass spectrometry and detection in human milk
6. Pyrroloquinoline quinone improves growth and reproductive performance in mice fed chemically defined diets
7. Crystal structure and characterization of pyrroloquinoline quinone disodium trihydrate
8. Potential physiological importance of pyrroloquinoline quinone
9. Pyrroloquinoline quinone inhibits the fibrillation of amyloid proteins
10. Kinetic study of the quenching reaction of singlet oxygen by Pyrroloquinolinequinol (PQQH(2), a reduced form of Pyrroloquinolinequinone) in micellar solution
11. Partial peptide of α-synuclein modified with small-molecule inhibitors specifically inhibits amyloid fibrillation of α-synuclein
12. The essential nutrient pyrroloquinoline quinone may act as a neuroprotectant by suppressing peroxynitrite formation
13. Nutritional biochemistry: A new redox-cofactor vitamin for mammals
14. Biochemistry: role of PQQ as a mammalian enzyme cofactor?
15. Biochemistry: is pyrroloquinoline quinone a vitamin?
16. Cloning and characterization of a novel human homolog* of mouse U26, a putative PQQ-dependent AAS dehydrogenase
17. Pyrroloquinoline quinone nutritional status alters lysine metabolism and modulates mitochondrial DNA content in the mouse and rat
18. Physiological importance of quinoenzymes and the O-quinone family of cofactors
19. The pyrroloquinoline quinone biosynthesis pathway revisited: a structural approach
20. Characterization of the glycine-dependent redox-cycling activity in animal fluids and tissues using specific inhibitors and activators: evidence for presence of PQQ
21. Redox-cycling detection of dialyzable pyrroloquinoline quinone and quinoproteins
22. Pyrroloquinoline quinone modulates mitochondrial quantity and function in mice
23. Altering pyrroloquinoline quinone nutritional status modulates mitochondrial, lipid, and energy metabolism in rats
24. Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects
25. The catalysis of redox cycling by pyrroloquinoline quinone (PQQ), PQQ derivatives, and isomers and the specificity of inhibitors
26. Specific detection of quinoproteins by redox-cycling staining
27. The generation of an organic free radical in substrate-reduced pig kidney diamine oxidase-cyanide
28. Primary structure of a pyrroloquinoline quinone (PQQ) containing peptide isolated from porcine kidney diamine oxidase
29. Evidence for PQQ as cofactor in 3,4-dihydroxyphenylalanine (dopa) decarboxylase of pig kidney
30. Dopamine beta-hydroxylase from bovine adrenal medulla contains covalently-bound pyrroloquinoline quinone
31. Spectral studies of bovine dopamine beta-hydroxylase. Absence of covalently bound pyrroloquinoline quinone
32. PQQ in plants (and animals)?
33. Status of the cofactor identity in copper oxidative enzymes
34. Redox regulation of cellular signalling
35. Kinetic study of the antioxidant activity of pyrroloquinolinequinol (PQQH(2), a reduced form of pyrroloquinolinequinone) in micellar solution
36. Pyrroloquinoline quinone stimulates epithelial cell proliferation by activating epidermal growth factor receptor through redox cycling
37. Pyrroloquinoline quinone, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves impaired glucose tolerance in diabetic KK-A(y) mice
38. Physiological functions of thioredoxin and thioredoxin reductase
39. Pyrroloquinoline quinone modulates the kinetic parameters of the mammalian selenoprotein thioredoxin reductase 1 and is an inhibitor of glutathione reductase
40. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells
41. The yin and yang of nrf2-regulated selenoproteins in carcinogenesis
42. Thioredoxin reductase inhibition elicits Nrf2-mediated responses in Clara cells: implications for oxidant-induced lung injury
43. Cytoprotective Nrf2 pathway is induced in chronically txnrd 1-deficient hepatocytes
44. Identification of transcriptional networks responding to pyrroloquinoline quinone dietary supplementation and their influence on thioredoxin expression, and the JAK/STAT and MAPK pathways
45. Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha
46. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression
47. Dietary pyrroloquinoline quinone: growth and immune response in BALB/c mice
48. Effects of Pyrroloquinoline Quinone (PQQ) Supplementation on Aerobic Exercise Performance and Indices of Mitochondrial Biogenesis in Untrained Men
49. Lactate, pyruvate, and lactate-to-pyruvate ratio during exercise and recovery
50. Systemic perturbations of key metabolites in diabetic rats during the evolution of diabetes studied by urine metabonomics
51. Urinary organic acids in infant malnutrition
52. Activation of Ras signaling pathways by pyrroloquinoline quinone in NIH3T3 mouse fibroblasts
53. Pro-oxidant action of pyrroloquinoline quinone: characterization of protein oxidative modifications
54. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor
55. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation
56. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate
57. Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance
58. Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?
59. SIRT1 metabolic actions: Integrating recent advances from mouse models
60. SIRT1 and energy metabolism
61. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer
62. SirT1 gain of function increases energy efficiency and prevents diabetes in mice
63. Sirt1 protects against high-fat diet-induced metabolic damage
64. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation
65. Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3
66. Intestinal absorption and tissue distribution of [14C]pyrroloquinoline quinone in mice
67. Uranium exerts acute toxicity by binding to pyrroloquinoline quinone cofactor
68. Conformation of coenzyme pyrroloquinoline quinone and role of Ca2+ in the catalytic mechanism of quinoprotein methanol dehydrogenase
69. Oxygen free radicals regulate NMDA receptor function via a redox modulatory site
70. Selective modulation of NMDA responses by reduction and oxidation
71. The modulation of N-methyl-D-aspartate receptors by redox and alkylating reagents in rat cortical neurones in vitro
72. Further evidence that pyrroloquinoline quinone interacts with the N-methyl-D-aspartate receptor redox site in rat cortical neurons in vitro
73. Interaction of the putative essential nutrient pyrroloquinoline quinone with the N-methyl-D-aspartate receptor redox modulatory site
74. Effects of pyrroloquinoline quinone on glutamate-induced production of reactive oxygen species in neurons
75. Pyrroloquinoline quinone rescues hippocampal neurons from glutamate-induced cell death through activation of Nrf2 and up-regulation of antioxidant genes
76. Pyrroloquinoline quinine protects rat brain cortex against acute glutamate-induced neurotoxicity
77. The neuroprotective action of pyrroloquinoline quinone against glutamate-induced apoptosis in hippocampal neurons is mediated through the activation of PI3K/Akt pathway
78. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication
79. Mechanism of toxicity in rotenone models of Parkinson's disease
80. Pyrroloquinoline quinone-conferred neuroprotection in rotenone models of Parkinson's disease
81. Stimulation of nerve growth factor production by pyrroloquinoline quinone and its derivatives in vitro and in vivo
82. Synthesis of esters of coenzyme PQQ and IPQ, and stimulation of nerve growth factor production
83. Cyclooxygenase induction is essential for NGF synthesis enhancement by NGF inducers in L-M cells
84. [The roles of PI3K/Akt pathway in proliferation of Schwann cells promoted by pyrroloquinoline quinone]
85. 15d-prostaglandin J2 enhancement of nerve growth factor-induced neurite outgrowth is blocked by the chemoattractant receptor- homologous molecule expressed on T-helper type 2 cells (CRTH2) antagonist CAY10471 in PC12 cells
86. Stimulation of NGF expression and secretion in 3T3-L1 adipocytes by prostaglandins PGD2, PGJ2, and Delta12-PGJ2
87. Prostaglandins are powerful inducers of NGF and BDNF production in mouse astrocyte cultures
88. Prostaglandin J2 and its metabolites promote neurite outgrowth induced by nerve growth factor in PC12 cells
89. Stimulation of nerve growth factor synthesis/secretion in mouse astroglial cells by coenzymes
90. Enhanced rat sciatic nerve regeneration through silicon tubes filled with pyrroloquinoline quinone
91. Nitric oxide via macrophage iNOS induces apoptosis following traumatic spinal cord injury
92. iNOS and nitrotyrosine expression after spinal cord injury
93. Pyrroloquinoline quinone attenuates iNOS gene expression in the injured spinal cord
94. Effect of pyrroloquinoline quinone on neuropathic pain following chronic constriction injury of the sciatic nerve in rats
95. The effect of adrenaline and of alpha- and beta-adrenergic blocking agents on ATP concentration and on incorporation of 32Pi into ATP in rat fat cells
96. Synthesis of monoesters of pyrroloquinoline quinone and imidazopyrroloquinoline, and radical scavenging activities using electron spin resonance in vitro and pharmacological activity in vivo
97. Is the antioxidant, anti-inflammatory putative new vitamin, PQQ, involved with nitric oxide in bone metabolism?
98. Glutamate receptors in epilepsy
99. Glutamate, GABA and epilepsy
100. Novel role for the NMDA receptor redox modulatory site in the pathophysiology of seizures
101. Dynamic changes in cerebral oxygenation in chemically induced seizures in rats: study by near-infrared spectrophotometry
102. Generalized seizures deplete brain energy reserves in normoxemic newborn monkeys
103. The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications
104. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy
105. The putative essential nutrient pyrroloquinoline quinone is neuroprotective in a rodent model of hypoxic/ischemic brain injury
106. Neuroprotection by pyrroloquinoline quinone (PQQ) in reversible middle cerebral artery occlusion in the adult rat
107. The neuroprotective effect of pyrroloquinoline quinone on traumatic brain injury
108. Pyrroloquinoline Quinone (PQQ) Prevents Cognitive Deficit Caused by Oxidative Stress in Rats
109. Protection of pyrroloquinoline quinone against methylmercury-induced neurotoxicity via reducing oxidative stress
110. In vitro protective effects of pyrroloquinoline quinone on methylmercury-induced neurotoxicity
111. Effect of vitamin E on learning and memory deficit in aged rats
112. Effect of the Antioxidant Supplement Pyrroloquinoline Quinone Disodium Salt (BioPQQ™) on Cognitive Functions
113. Pyrroloquinoline quinone (PQQ) decreases myocardial infarct size and improves cardiac function in rat models of ischemia and ischemia/reperfusion
114. Pyrroloquinoline quinone preserves mitochondrial function and prevents oxidative injury in adult rat cardiac myocytes
115. Comparison of pyrroloquinoline quinone and/or metoprolol on myocardial infarct size and mitochondrial damage in a rat model of ischemia/reperfusion injury
116. The connection between C-reactive protein and atherosclerosis
117. Susceptibility of human metabolic phenotypes to dietary modulation
118. Skeletal muscle adaptation to fatty acid depends on coordinated actions of the PPARs and PGC1 alpha: implications for metabolic disease
119. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ)
120. NFATc1: functions in osteoclasts
121. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts
122. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation
123. Fos/AP-1 proteins in bone and the immune system
124. Mechanisms of interferon-beta effects on bone homeostasis
125. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta
126. Interplay between interferon and other cytokine systems in bone metabolism
127. Role of dietary proteins and amino acids in the pathogenesis of insulin resistance
128. Influence of adding pyrroloquinoline quinone to parenteral nutrition on gut-associated lymphoid tissue
129. Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide
130. Epicatechin in human plasma: in vivo determination and effect of chocolate consumption on plasma oxidation status
131. Production and radioprotective effects of pyrroloquinoline quinone
132. The protective effect of pyrroloquinoline quinone and its derivatives against carbon tetrachloride-induced liver injury of rats
133. New developments in oxidative fermentation
134. Escherichia coli is unable to produce pyrroloquinoline quinone (PQQ)
135. Does the intestinal microflora synthesize pyrroloquinoline quinone?
136. Role of glutathione in augmenting the anticancer activity of pyrroloquinoline quinone (PQQ)
137. Antioxidant and pro-oxidant properties of pyrroloquinoline quinone (PQQ): implications for its function in biological systems
138. Effect of pyrroloquinoline quinone (PQQ) on melanogenic protein expression in murine B16 melanoma
139. Pyrroloquinoline quinone (PQQ) inhibits the expression of tyrosinase mRNA by alpha-melanocyte stimulating hormone in murine B16 melanoma cells
140. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity
141. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease
142. Alpha-synuclein in Lewy bodies
143. Engineered alpha-synuclein prevents wild type and familial Parkin variant fibril formation
144. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine
145. Structural and functional implications of C-terminal regions of alpha-synuclein
146. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils
147. The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein
148. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease
149. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls
150. Pyrroloquinoline quinone is a potent neuroprotective nutrient against 6-hydroxydopamine-induced neurotoxicity
151. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition
152. Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection
153. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism
154. Pyrroloquinoline quinone prevents oxidative stress-induced neuronal death probably through changes in oxidative status of DJ-1
155. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein
156. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein
157. Protective effect of pyrroloquinoline quinone against Abeta-induced neurotoxicity in human neuroblastoma SH-SY5Y cells
158. Nephrotoxicity of pyrroloquinoline quinone in rats
159. Genotoxicity of pyrroloquinoline quinone (PQQ) disodium salt (BioPQQ™)

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!